Amylyx Pharmaceuticals, Inc. Common Stock

AMLXNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
13.32 USD
↘ 0.99 (6.92%)AT CLOSE (11:59 AM EDT)
13.30
↘ 0.02 (0.15%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
13.30
↘ 0.02 (0.15%)
🔴Market: CLOSED
Open?$14.25
High?$14.47
Low?$12.97
Prev. Close?$14.31
Volume?1.7M
Avg. Volume?1.1M
VWAP?$13.50
Rel. Volume?1.54x
Bid / Ask
Bid?$11.32 × 100
Ask?$15.12 × 100
Spread?$3.80
Midpoint?$13.22
Valuation & Ratios
Market Cap?1.5B
Shares Out?111.2M
Float?87.4M
Float %?79.6%
P/E Ratio?N/A
P/B Ratio?5.42
EPS?-$1.35
Dividend?0.00%
Ex-Dividend?N/A

Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is currently trading at $13.32. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. AMLX is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsBiotech - Drug Development›Neuroscience & CNS
Employees
136
Market Cap
1.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.amylyx.com
Listed
2022-01-07
Address
55 CAMBRIDGE PARKWAY
CAMBRIDGE, MA 02142
Phone: 617-682-0917
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?39.00Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?16.61%High
Short Interest?14.5M
Days to Cover?12.2
Free Float87.4M
Avg Daily Volume1.2M
Settlement Date2026-05-15
Financial Health
Current Ratio?17.85Strong
Quick Ratio?17.85Strong
Cash Ratio?14.35Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
34
5.42FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-54.9%WEAK▾
ROA?
S&P
3
-51.1%WEAK▾
Cash Flow & Enterprise
FCF?$-120528000
Enterprise Value?$1.3B
Fundamentals ratios updated end of day
MarketsMoversWatchlist